A
ESMO-MCBS v1.1
Scorecard version: 1
Indication details
- Tumour Type
- Skin Cancers
- Tumour Sub-type
- Melanoma
- Tumour stage
- Adjuvant
- Control Arm
- Placebo
- Treatment Setting
- Adjuvant stage III melanoma
- Trial Name
- EORTC 18071
Primary Outcome(s)
- Primary Outcome(s)
- 5-years DFS
- Evaluated Outcome
- DFS
- Form(s)
- Form 1
Outcome Data
- OS Control
- 54.40 %
- OS Gain
- 11 %
- OS HR
- 0.76 (0.64-0.89)
- QoL Comment
- No QoL benefit
Final Score (after adjustments)
- Final curative score
- A
- Last update
- 22.07.2020
DFS, disease-free survival; DoR, duration of response; EFS, event-free survival; FFS, failure-free survival; HR, hazard ratio; iDFS, invasive disease-free survival; ITT, intention to treat; MFS, metastasis-free survival; ORR, overall response rate; OS, overall survival; pCR, pathologic complete response/remission; PFS, progression-free survival; QoL, quality of life; RFS, relapse-free survival; RR, response rate; SD, stable disease; SSA, somatostatin analogue; SSTR, somatostatin receptor; TKI, tyrosine kinase inhibitor, TTP, time to progression